7Chang TC, Kao SC, Hsiao YL, et al. Therapeutic responses to corticosteroids in Graves' ophthalmopathy[ J]. J Formos Med Assoc, 1996,95( 11 ) :833-838.
9Marcocci C ,Bartalena L,Tanda ML, et al. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of prospective, single-blind, randomized study [ J]. J Clin Endocrinol Metab,2001,86(8) :3562-3567.
9Kendall-Taylor P. Thyrotoxicosis. In: Grossman A (eds). Clinical Endocrinology. London: Blackwell Science Ltd, 1998,328-358.
10Mori S, Yoshikawa N, Horimoto M, et al. Thyroid stimulating antibody in sera of Graves′ ophthalmopathy patients as a possible marker for predicting the efficacy of methylprednisolone pulse therapy. Endocr J, 1995,42:442-448.
7Lehmann GM, Feldon SE, Smith TJ, et al. Immune mechanisms in thyroid eye disease. Thyroid, 2008, 18(9): 959-965.
8E1-Kaissi S, Frauman AG, Wall JR. Thyroid-associated ophthal- mopathy: a practical guide to classification, natural history and management. Intern Med J, 2004,34(8): 482-491.
9Cukierman CLF, Henriques JLM YR. Orbitopatia tireoidea: andlise cllnica e epidemiologica. Rev Bras Oftalmol, 2000, 59(8): 578-585.
10Bartalena L, Baldeschi L, Dickinson A, et al. Consensus statement of the European Group on Graves" orbitopathy (EUGOGO) on man- agement of GO. Eur J Endocrinol, 2008,158(3): 273-285.
